PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PARP Inhibitors: Clinical Relevance, Mechanisms of Action and Tumor Resistance
Authors
Keywords
-
Journal
Frontiers in Cell and Developmental Biology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2020-09-09
DOI
10.3389/fcell.2020.564601
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- TRIP13 regulates DNA repair pathway choice through REV7 conformational change
- (2020) Connor S. Clairmont et al. NATURE CELL BIOLOGY
- A Phase I/II Study of Veliparib (ABT-888) with Radiation and Temozolomide in Newly Diagnosed Diffuse Pontine Glioma: A Pediatric Brain Tumor Consortium Study
- (2020) P A Baxter et al. NEURO-ONCOLOGY
- The kinase polypharmacology landscape of clinical PARP inhibitors
- (2020) Albert A. Antolin et al. Scientific Reports
- Olaparib for Metastatic Castration-Resistant Prostate Cancer
- (2020) Johann de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Ubiquitin Ligase TRIP12 Limits PARP1 Trapping and Constrains PARP Inhibitor Efficiency
- (2020) Marco Gatti et al. Cell Reports
- Pharmacologic Characterization of Fluzoparib, a Novel Poly(ADP-ribose) polymerase (PARP) Inhibitor Undergoing Clinical Trials
- (2019) Lei Wang et al. CANCER SCIENCE
- A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer
- (2019) R. Tuli et al. EBioMedicine
- NADP+ is an endogenous PARP inhibitor in DNA damage response and tumor suppression
- (2019) Chunjing Bian et al. Nature Communications
- The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis
- (2019) Mok Oh et al. PROSTATE
- The ATP-bound conformation of the Mre11–Rad50 complex is essential for Tel1/ATM activation
- (2019) Corinne Cassani et al. NUCLEIC ACIDS RESEARCH
- PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms
- (2019) Xuan Jiang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Roadmap of DNA methylation in breast cancer identifies novel prognostic biomarkers
- (2019) Bernardo P. de Almeida et al. BMC CANCER
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Targeting ADP-ribosylation by PARP inhibitors in acute myeloid leukaemia and related disorders
- (2019) Isabella Faraoni et al. BIOCHEMICAL PHARMACOLOGY
- 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer
- (2019) Rachel M. Hurley et al. GYNECOLOGIC ONCOLOGY
- Universal tumor DNA BRCA1/2 testing of ovarian cancer: prescreening PARPi treatment and genetic predisposition
- (2019) Janet R Vos et al. JNCI-Journal of the National Cancer Institute
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy
- (2019) Yong Fang et al. CANCER CELL
- Identification of Novel Biomarkers of Homologous Recombination Defect in DNA Repair to Predict Sensitivity of Prostate Cancer Cells to PARP-Inhibitors
- (2019) Daniela Criscuolo et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21
- (2019) Dae-Seok Kim et al. MOLECULAR CELL
- Tumour lineage shapes BRCA-mediated phenotypes
- (2019) Philip Jonsson et al. NATURE
- Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
- (2019) Talia Golan et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA2 abrogation triggers innate immune responses potentiated by treatment with PARP inhibitors
- (2019) Timo Reisländer et al. Nature Communications
- A systematic review of the international prevalence of BRCA mutation in breast cancer
- (2019) Nigel Armstrong et al. Clinical Epidemiology
- DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes
- (2019) Thiago Vidotto et al. Journal for ImmunoTherapy of Cancer
- Aberrant DNA Methylation in Acute Myeloid Leukemia and Its Clinical Implications
- (2019) Xianwen Yang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Current Clinical Strategies of Pancreatic Cancer Treatment and Open Molecular Questions
- (2019) Maximilian Brunner et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- BRCA mutation frequency and clinical features of ovarian cancer patients: A report from a Chinese study group
- (2019) Hualei Bu et al. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH
- Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
- (2019) Michael Friedlander et al. LANCET ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer
- (2019) Anna F. Farago et al. Cancer Discovery
- 846PDPreliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): Updated analyses
- (2019) W Abida et al. ANNALS OF ONCOLOGY
- Fluzoparib increases radiation sensitivity of non-small cell lung cancer (NSCLC) cells without BRCA1/2 mutation, a novel PARP1 inhibitor undergoing clinical trials
- (2019) Jing Luo et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
- (2019) Sylvie M. Noordermeer et al. TRENDS IN CELL BIOLOGY
- AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity
- (2019) Jacqueline H. L. Fok et al. Nature Communications
- Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial
- (2019) Joaquin Mateo et al. LANCET ONCOLOGY
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- Barrier-to-autointegration factor 1 (Banf1) regulates poly [ADP-ribose] polymerase 1 (PARP1) activity following oxidative DNA damage
- (2019) Emma Bolderson et al. Nature Communications
- Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death
- (2019) Jerry H. Houl et al. Nature Communications
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity
- (2018) Rajat Gupta et al. CELL
- BRCA2 Reversion Mutation Associated With Acquired Resistance to Olaparib in Estrogen Receptor-positive Breast Cancer Detected by Genomic Profiling of Tissue and Liquid Biopsy
- (2018) Erica L. Gornstein et al. Clinical Breast Cancer
- Talazoparib is a Potent Radiosensitizer in Small Cell Lung Cancer Cell Lines and Xenografts
- (2018) James H Laird et al. CLINICAL CANCER RESEARCH
- An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations
- (2018) Nicholas Pulliam et al. CLINICAL CANCER RESEARCH
- A systematic review on the frequency of BRCA promoter methylation in breast and ovarian carcinomas of BRCA germline mutation carriers: Mutually exclusive, or not?
- (2018) Shoko Vos et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- The cGAS–cGAMP–STING pathway connects DNA damage to inflammation, senescence, and cancer
- (2018) Tuo Li et al. JOURNAL OF EXPERIMENTAL MEDICINE
- The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication
- (2018) Hana Hanzlikova et al. MOLECULAR CELL
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- Assembling a protective shield
- (2018) Roger A Greenberg NATURE CELL BIOLOGY
- Analysis of PARP inhibitor toxicity by multidimensional fluorescence microscopy reveals mechanisms of sensitivity and resistance
- (2018) Jone Michelena et al. Nature Communications
- The multifunctional protein YB-1 potentiates PARP1 activity and decreases the efficiency of PARP1 inhibitors
- (2018) Elizaveta Alemasova et al. Oncotarget
- Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial
- (2018) J Ettl et al. ANNALS OF ONCOLOGY
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments
- (2018) Hongwei Liao et al. EMBO REPORTS
- High speed of fork progression induces DNA replication stress and genomic instability
- (2018) Apolinar Maya-Mendoza et al. NATURE
- Superfast DNA replication causes damage in cancer cells
- (2018) Annabel Quinet et al. NATURE
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
- (2018) Olga Kondrashova et al. Nature Communications
- Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer
- (2018) Dan Le et al. Expert Review of Clinical Pharmacology
- Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
- (2018) Michael Friedlander et al. BRITISH JOURNAL OF CANCER
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial
- (2018) S.A. Hurvitz et al. EUROPEAN JOURNAL OF CANCER
- PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
- (2018) Todd A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- Epidemiology of lung cancer in China
- (2018) Maomao Cao et al. Thoracic Cancer
- Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response
- (2018) Paola Francica et al. Genome Medicine
- Pattern Recognition Receptors and the Host Cell Death Molecular Machinery
- (2018) Gustavo P. Amarante-Mendes et al. Frontiers in Immunology
- BRCA Mutations and Breast Cancer Prevention
- (2018) Joanne Kotsopoulos Cancers
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancer
- (2018) Roman M. Chabanon et al. JOURNAL OF CLINICAL INVESTIGATION
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
- (2017) Amit M. Oza et al. GYNECOLOGIC ONCOLOGY
- Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing
- (2017) Diana Mandelker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- PARP1 Trapping and DNA Replication Stress Enhance Radiosensitization with Combined WEE1 and PARP Inhibitors
- (2017) Leslie A. Parsels et al. MOLECULAR CANCER RESEARCH
- Serine ADP-Ribosylation Depends on HPF1
- (2017) Juan José Bonfiglio et al. MOLECULAR CELL
- Restoration of Replication Fork Stability in BRCA1- and BRCA2-Deficient Cells by Inactivation of SNF2-Family Fork Remodelers
- (2017) Angelo Taglialatela et al. MOLECULAR CELL
- EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
- (2017) Beatrice Rondinelli et al. NATURE CELL BIOLOGY
- The DNA methyltransferase family: a versatile toolkit for epigenetic regulation
- (2017) Frank Lyko NATURE REVIEWS GENETICS
- The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
- (2017) Arnab Ray Chaudhuri et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- PARP1 changes from three-dimensional DNA damage searching to one-dimensional diffusion after auto-PARylation or in the presence of APE1
- (2017) Lili Liu et al. NUCLEIC ACIDS RESEARCH
- EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer
- (2017) H Yamaguchi et al. ONCOGENE
- Triple-negative breast cancer and the potential for targeted therapy
- (2017) Jing-Ru Jhan et al. PHARMACOGENOMICS
- Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review
- (2017) Michal Chovanec et al. Targeted Oncology
- Rucaparib: the past, present, and future of a newly approved PARP inhibitor for ovarian cancer
- (2017) LE Dockery et al. OncoTargets and Therapy
- Progression through mitosis promotes PARP inhibitor-induced cytotoxicity in homologous recombination-deficient cancer cells
- (2017) Pepijn M. Schoonen et al. Nature Communications
- Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
- (2017) Johann de Bono et al. Cancer Discovery
- Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2017) Olga Kondrashova et al. Cancer Discovery
- PARP inhibition causes premature loss of cohesion in cancer cells
- (2017) Eva Kukolj et al. Oncotarget
- The Role of the Core Non-Homologous End Joining Factors in Carcinogenesis and Cancer
- (2017) et al. Cancers
- Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study
- (2017) Alison Pearce et al. PLoS One
- Y-box-binding protein 1 as a non-canonical factor of base excision repair
- (2016) Elizaveta E. Alemasova et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
- (2016) Nidal E. Muvarak et al. CANCER CELL
- Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms
- (2016) K. W. Pratz et al. CLINICAL CANCER RESEARCH
- Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer
- (2016) M. L. Telli et al. CLINICAL CANCER RESEARCH
- Patients’ perception of chemotherapy side effects: Expectations, doctor-patient communication and impact on quality of life - An Italian survey
- (2016) Domenica Lorusso et al. EUROPEAN JOURNAL OF CANCER CARE
- Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes
- (2016) Dong Wang et al. GYNECOLOGIC ONCOLOGY
- Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
- (2016) Pierre Chabot et al. JOURNAL OF NEURO-ONCOLOGY
- HPF1/C4orf27 Is a PARP-1-Interacting Protein that Regulates PARP-1 ADP-Ribosylation Activity
- (2016) Ian Gibbs-Seymour et al. MOLECULAR CELL
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Serine is a new target residue for endogenous ADP-ribosylation on histones
- (2016) Orsolya Leidecker et al. Nature Chemical Biology
- Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
- (2016) Angela George et al. Nature Reviews Clinical Oncology
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin
- (2016) Hana Hanzlikova et al. NUCLEIC ACIDS RESEARCH
- Protein dynamics of human RPA and RAD51 on ssDNA during assembly and disassembly of the RAD51 filament
- (2016) Chu Jian Ma et al. NUCLEIC ACIDS RESEARCH
- Targeting WEE1 Kinase in Cancer
- (2016) Christopher J. Matheson et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- AML associated oncofusion proteins PML-RARA, AML1-ETO and CBFB-MYH11 target RUNX/ETS-factor binding sites to modulate H3ac levels and drive leukemogenesis
- (2016) Abhishek A. Singh et al. Oncotarget
- Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1 -Mutant Ovarian Cancer
- (2016) Young Eun Choi et al. Cell Reports
- Sam68 Is Required for DNA Damage Responses via Regulating Poly(ADP-ribosyl)ation
- (2016) Xin Sun et al. PLOS BIOLOGY
- Sam68/KHDRBS1-dependent NF-κB activation confers radioprotection to the colon epithelium in γ-irradiated mice
- (2016) Kai Fu et al. eLife
- Sam68/KHDRBS1 is critical for colon tumorigenesis by regulating genotoxic stress-induced NF-κB activation
- (2016) Kai Fu et al. eLife
- Measuring quality of life after radical prostatectomy from the patient’s perspective
- (2016) Joseph L. Chin CUAJ-Canadian Urological Association Journal
- DAMPs, ageing, and cancer: The ‘DAMP Hypothesis’
- (2015) Jin Huang et al. AGEING RESEARCH REVIEWS
- Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development
- (2015) Clare L. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Monotherapy in Patients With Advanced Cancer and a GermlineBRCA1/2Mutation
- (2015) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- In cellulophosphorylation of XRCC4 Ser320 by DNA-PK induced by DNA damage
- (2015) Mukesh Kumar Sharma et al. JOURNAL OF RADIATION RESEARCH
- Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors
- (2015) T. A. Hopkins et al. MOLECULAR CANCER RESEARCH
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors
- (2015) Maria Teresa Esposito et al. NATURE MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulators of homologous recombination repair as novel targets for cancer treatment
- (2015) Małgorzata Krajewska et al. Frontiers in Genetics
- PARP targeting counteracts gliomagenesis through induction of mitotic catastrophe and aggravation of deficiency in homologous recombination in PTEN-mutant glioma
- (2015) Jara Majuelos-Melguizo et al. Oncotarget
- The nuclear γ-H2AX apoptotic ring: implications for cancers and autoimmune diseases
- (2014) Stéphanie Solier et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Combined Inhibition of Wee1 and PARP1/2 for Radiosensitization in Pancreatic Cancer
- (2014) D. Karnak et al. CLINICAL CANCER RESEARCH
- Holliday junction resolution: Regulation in space and time
- (2014) Joao Matos et al. DNA REPAIR
- Transcriptional Roles of PARP1 in Cancer
- (2014) Matthew J. Schiewer et al. MOLECULAR CANCER RESEARCH
- Base Excision Repair Defects Invoke Hypersensitivity to PARP Inhibition
- (2014) Julie K. Horton et al. MOLECULAR CANCER RESEARCH
- PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways
- (2014) Carole Beck et al. NUCLEIC ACIDS RESEARCH
- PARP-2 and PARP-3 are selectively activated by 5′ phosphorylated DNA breaks through an allosteric regulatory mechanism shared with PARP-1
- (2014) Marie-France Langelier et al. NUCLEIC ACIDS RESEARCH
- PARP1–TDP1 coupling for the repair of topoisomerase I–induced DNA damage
- (2014) Benu Brata Das et al. NUCLEIC ACIDS RESEARCH
- Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
- (2014) Romana Koppensteiner et al. PLoS One
- Triple-negative breast cancer frequency and type of BRCA mutation: Clues from Sardinia
- (2014) GRAZIA PALOMBA et al. Oncology Letters
- Vulnerabilities of PTEN-TP53-Deficient Prostate Cancers to Compound PARP-PI3K Inhibition
- (2014) E. Gonzalez-Billalabeitia et al. Cancer Discovery
- PARP1-Driven Poly-ADP-Ribosylation Regulates BRCA1 Function in Homologous Recombination-Mediated DNA Repair
- (2014) Y. Hu et al. Cancer Discovery
- MicroRNAs down-regulate homologous recombination in the G1 phase of cycling cells to maintain genomic stability
- (2014) Young Eun Choi et al. eLife
- A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
- (2013) Ruth Plummer et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
- (2013) Y. Shen et al. CLINICAL CANCER RESEARCH
- Microsatellite instability induced mutations in DNA repair genes CtIP and MRE11 confer hypersensitivity to poly (ADP-ribose) polymerase inhibitors in myeloid malignancies
- (2013) T. J. Gaymes et al. HAEMATOLOGICA
- Role of Replication Protein A in Double Holliday Junction Dissolution Mediated by the BLM-Topo IIIα-RMI1-RMI2 Protein Complex
- (2013) Xiaoyu Xue et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial
- (2013) Shahneen K Sandhu et al. LANCET ONCOLOGY
- RAD51C-Deficient Cancer Cells Are Highly Sensitive to the PARP Inhibitor Olaparib
- (2013) A. Min et al. MOLECULAR CANCER THERAPEUTICS
- Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
- (2013) J. Murai et al. MOLECULAR CANCER THERAPEUTICS
- Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
- (2013) Y. Maede et al. MOLECULAR CANCER THERAPEUTICS
- RPA Coordinates DNA End Resection and Prevents Formation of DNA Hairpins
- (2013) Huan Chen et al. MOLECULAR CELL
- The PARP3- and ATM-dependent phosphorylation of APLF facilitates DNA double-strand break repair
- (2013) Amanda L. Fenton et al. NUCLEIC ACIDS RESEARCH
- Poly(ADP-ribose) binding to Chk1 at stalled replication forks is required for S-phase checkpoint activation
- (2013) WooKee Min et al. Nature Communications
- The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
- (2012) J Iqbal et al. BRITISH JOURNAL OF CANCER
- PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
- (2012) J. C. Brenner et al. CANCER RESEARCH
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
- (2012) S. Ying et al. CANCER RESEARCH
- PARP1 promotes nucleotide excision repair through DDB2 stabilization and recruitment of ALC1
- (2012) Alex Pines et al. JOURNAL OF CELL BIOLOGY
- The p65 subunit of NF-κB and PARP1 assist Snail1 in activating fibronectin transcription
- (2012) Jelena Stanisavljevic et al. JOURNAL OF CELL SCIENCE
- The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
- (2012) Ammar A E Ali et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Poly(ADP-ribosyl)ation of p53 induces gene-specific transcriptional repression of MTA1
- (2012) M-H Lee et al. ONCOGENE
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells
- (2011) Zhiyong Mao et al. CELL CYCLE
- Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer
- (2011) Céline Montavon et al. GYNECOLOGIC ONCOLOGY
- PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
- (2011) Stuart L. Rulten et al. MOLECULAR CELL
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression
- (2011) C. Boehler et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Temozolomide: Mechanisms of Action, Repair and Resistance
- (2011) Jihong Zhang et al. Current Molecular Pharmacology
- Secondary BRCA1 and BRCA2 alterations and acquired chemoresistance
- (2010) Weixin Wang et al. CANCER BIOLOGY & THERAPY
- 6-Thioguanine Selectively Kills BRCA2-Defective Tumors and Overcomes PARP Inhibitor Resistance
- (2010) N. Issaeva et al. CANCER RESEARCH
- Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells
- (2010) P. Gottipati et al. CANCER RESEARCH
- MicroRNA: Biogenesis, Function and Role in Cancer
- (2010) Leigh-Ann MacFarlane et al. CURRENT GENOMICS
- Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2
- (2010) Nancie Petrucelli et al. GENETICS IN MEDICINE
- Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses inBRCACarrier Ovarian Cancer Correlating With Platinum-Free Interval
- (2010) Peter C. Fong et al. JOURNAL OF CLINICAL ONCOLOGY
- The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
- (2010) Raga Krishnakumar et al. MOLECULAR CELL
- Purified human BRCA2 stimulates RAD51-mediated recombination
- (2010) Ryan B. Jensen et al. NATURE
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate
- (2010) C. E. Strom et al. NUCLEIC ACIDS RESEARCH
- BRCA1andBRCA2mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer
- (2009) Michael J. Hall et al. CANCER
- PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination
- (2009) Helen E Bryant et al. EMBO JOURNAL
- Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies
- (2009) Shivaani Kummar et al. JOURNAL OF CLINICAL ONCOLOGY
- Cells deficient in PARP-1 show an accelerated accumulation of DNA single strand breaks, but not AP sites, over the PARP-1-proficient cells exposed to MMS
- (2009) Brian F. Pachkowski et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- CtIP-BRCA1 modulates the choice of DNA double-strand-break repair pathway throughout the cell cycle
- (2009) Maximina H. Yun et al. NATURE
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sgs1 Helicase and Two Nucleases Dna2 and Exo1 Resect DNA Double-Strand Break Ends
- (2008) Zhu Zhu et al. CELL
- A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
- (2008) Nicholas C Turner et al. EMBO JOURNAL
- Replication-Dependent Radiosensitization of Human Glioma Cells by Inhibition of Poly(ADP-Ribose) Polymerase: Mechanisms and Therapeutic Potential
- (2008) Fiona A. Dungey et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- PARP-1 ensures regulation of replication fork progression by homologous recombination on damaged DNA
- (2008) Kazuto Sugimura et al. JOURNAL OF CELL BIOLOGY
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility
- (2008) C. Godon et al. NUCLEIC ACIDS RESEARCH
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
- (2008) S. Rottenberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started